Hypoparathyroidism Effectively Managed With TransCon PTH in Phase 3 Trial
Positive topline results were announced from a phase 3 trial evaluating the efficacy and safety of TransCon PTH in adults with hypoparathyroidism.
Source: empr.com
Page 3 - Physical Functioning News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Physical Functioning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Physical Functioning Today - Breaking & Trending Today
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control . – TransCon PTH demonstrated statistically... | March 13, 2022
Source: marketscreener.com
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). – TransCon...
Source: globenewswire.com
COVID-19: Orissa High Court switches to virtual hearing of cases from Jan 10 to Feb 4
In view of the rise in COVID-19 cases, the Orissa High Court has decided to hear cases through video conference from January 10, 2022 to February 4, 2022.
Source: barandbench.com
Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities
Share this article Share this article BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ -- Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life scores (HRQoL) compared to placebo.* Following the 68-week ...
Source: prnewswire.co.uk